Boehringer Ingelheim buys oncology biotech for up to $1.3B

Boehringer In­gel­heim is pay­ing up to $1.3 bil­lion to ac­quire a rel­a­tive­ly un­known im­muno-on­col­o­gy biotech out of La Jol­la, CA.

The Ger­man drug gi­ant …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

How AI Can Reinvent Nurse Staffing

 Danielle Bowie, Chief Nursing Officer, Trusted Health  Artificial intelligence is transforming the way the healthcare industry operates, from clinical decision-making to front-office tasks to financial workflows. Perhaps one of the

Read More »